sLea/CA19-9 directly impacts the activation of EGFR and potentiates downstream signaling in pancreatic disease by decorating the EGFR ligand Fibulin-3 (Engle et al., 2019; Fig. 1). Here, EGFR is linked to pancreas disorder.